Kornimate/medical-research-clean huggingface dataset:
function and balance for inpatient rehabilitation

Conditions: Solid Tumors

Summary: objectives: primary objectives: to determine the change in functional tests of postural control of cancer patients who have completed acute inpatient rehabilitation or complete rehabilitation through mobile team from discharge at 21-60 days (+/- 3) after discharge. secondary objectives: to assess the correlations between the functional tests of postural control, the balance test and the amount of exercise per week.

to be enrolled in this study, you must be able to walk with or without an assistant device (such as a cane or a walker). study procedures: if you are found to be eligible to take part in this study, you will do a combination of walking and balance tests twice, once on the day you leave the rehabilitation center or hospital, and again at a return visit 21-60 days (+/-3) later. for the first test, you will get up from a chair and walk 10 feet as quickly, but as safely, as possible. you will then return to the chair and sit again. for the second test, you will walk 25 feet, turn around, and walk back to the starting point as fast and as safely as you can. both tests will be timed by the study staff. you will also do a balance test on a machine. you will stand on a platform with a rail to hold on to. you will shift your weight and try to keep your balance and center of gravity, which will be shown on a screen. you will be given a diary to record any physical exercise you are doing from the time you leave the rehabilitation center to your return visit 21-60 days (+/-3) later. you will be asked to record what kind of exercises (home exercise, home health therapy, or outpatient therapy treatment) you do and for how many hours. it should take about 5 minutes to fill out the diary each time. you will complete a questionnaire that asks you about your symptoms, such as pain. you will complete it when you leave the rehabilitation program and again at the study visit 21-60 days (+/-3) later. it should take about 5 minutes to complete the questionnaire. length of study: you will be off study after you complete the second questionnaire. this is an investigational study. up to 58 patients will take part in this study. all will be enrolled at m. d. anderson.

Eligibility criteria:
inclusion criteria: 1. patients, or the legal guardians of patients, must have the ability to understand and willingness to sign a written informed consent document. 2. patients must be able to ambulate with or without assistant device, without assistance from a person. 3. patients must have undergone acute inpatient rehabilitation at mdacc or undergone rehabilitation through mobile team. exclusion criteria: 1. patients who decline to participate or who are determined incapable of completing the research. 2. active cns disease, such as clinically-evident metastases or leptomeningeal disease, dementia, or encephalopathy. 3. patient who is not willing or able to come back for 4+/-1 week routine follow-up.

Keywords: solid tumors acute inpatient rehabilitation postural instability balance function walking questionnaire survey
mindfulness rounds initiative - a short mindfulness-based program for a busy workplace

Conditions: Healthcare Practitioner Stress; Patient Satisfaction

Summary: an 8 week course of mindfulness education and practices will be presented to all staff, patients, and visitors voluntarily attending the thrice weekly presentations. the goal is to reduce staff stress, improve communication, enhance patient satisfaction, and improve quality of care.

"mindfulness rounds" care-giver well-being is recognized as an important goal in decreasing burnout, increasing job satisfaction, and may have implications in improving quality of care and patient satisfaction. mindfulness training is a well-studied tool used to enhance care-giver well-being. the impact of a mindfulness training experience for caregivers, support staff, and patients and their families working together in a hospital unit on patient satisfaction has not been well studied, if at all. the researchers propose instituting a pilot program of mindfulness rounds on a given hospital unit and assessing the effect on employee well-being, patient satisfaction, and quality of care. introduction: the physical and mental health of healthcare practitioners (hcps) has become an area of attention and research in recent years as hcp burnout and suicide are now openly discussed concerns in medicine. well-being education is now a required curricula component by the accreditation council for graduate medical education (acgme). mindfulness is a technique and philosophical concept which has received significant attention in the medical literature as a tool for increasing hcp well-being. mindfulness describes the idea of maintaining a conscious presence in the present, of avoiding obsessing about the past or the future, and of continuously being aware of, and grateful for, the things we have in life as opposed to the things we don't. mindfulness-based stress reduction (mbsr) is one particular system, developed by jon kabat-zinn over 30 years ago, which has been built into a well-structured certified training program for teaching mindfulness. numerous studies have used mbsr or similar techniques to advance hcp psychologic well-being, and while some have investigated a variety of hcp training techniques to improve the patient experience, few have sought to explore a relationship between the impact of mindfulness training for hcp on patient satisfaction, quality of care outcomes, and hcp overall health. to the investigators' knowledge, no one has sought to bring mindfulness education to an entire hospital unit - physicians, nurses, support staff, as well as patients and their families wherever possible - with the goal of improving both hcp and the overall patient experience. the researchers propose instituting a pilot program of mindfulness rounds on a given hospital unit and assessing the effect on employee well-being, patient satisfaction, and quality of care.

Eligibility criteria:
inclusion criteria: - employees on the units exclusion criteria: - none

Keywords: mindfulness stress pain scores patient satisfaction perceived stress scale mbsr
urinary activin a as apredictive marker for assessement of acute kidney injury severity in patient admitted at assuit university hospital

Conditions: Urinary Activin A in AKI

Summary: urinary activin a as amarker for assessement of acute kidney injury severity in patient admitted at assuit university hospital

acute kidney injury has been ahealth problem all over the world , it's prevelance in developing and developed countries is increasing due to pre renal , renal , post renal causes . estimates of aki prevalence range from \<1% to 66%. these variations can be explained by not only population differences but also inconsistent use of standardized aki classification criteria. the aetiology and incidence of aki also differ between high-income and low-to-middle-income countries.(1) * it can be presented in different stages according to akin classification (stage l (increase in serum creatinine ≥0.3md/dl (≥26.4μmol/l) or increase to \>150% to 200% (1.5 fold to 2 fold) from baseline , and urine output (\ 6 h )) * stage ll (increase to \>200% to 300% (\>2 fold to 3 fold) from baseline) , and urine output (\ 12 h )) * stage lll(increase in serum creatinine to \>300% (\>3 fold) from baseline, or serum creatinine \>4.0mg/dl (\>354μmol/l) with acute increase of atleast 0.5mg/dl ) urine output(\<0.3ml/kg/hr for 24 hours, or anuria for 12 hours). (2) * in ischemic kidney, there is acytokine belong to the transforming growth factor (tgf)-b ( activin a) that regulates the growth and differantiation of cell in variuos organs was significantly increasd in ischemic kidney . (3) * level of activin a in urine correlate to the severity of the acute kidney injury (aki), as the level of urinary activin a in first stages of acute kidney injury is less than the second and third stages . (4) * so follow up of urinary activin a in patients with acute kidney injury can be avery useful biomarker for assessement of severity of acute kidney injury. (4)

Eligibility criteria:
inclusion criteria: * the study will include patient with acute kidney injury with no history of chronic kidney diseases exclusion criteria: * patient with history of chronic kidney diseases , diseases associated with icreased activin a level such as ( heart failure , cancers , copd , systemic sclerosis ,pregnant , viral infection , and mycosis fungoides and sézary syndrom
vinorelbine in treating older patients with stage iiib or stage iv non-small cell lung cancer

Conditions: Lung Cancer

Summary: rationale: drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. purpose: phase ii trial to study the effectiveness of vinorelbine taken by mouth in treating older patients who have stage iiib or stage iv non-small cell lung cancer.

objectives: i. determine the objective response rate in elderly patients with stage iiib or iv non-small cell lung cancer treated with oral vinorelbine. ii. determine the time to progression in patients treated with this drug. iii. determine the toxicity of this drug in these patients. iv. determine whether there is a perceived preference for this oral administration in these patients. v. determine the quality of life of these patients when treated with this drug. vi. assess individual variation in responses, pharmacokinetic parameters, and/or biological correlates in patients treated with this drug. outline: patients receive oral vinorelbine on days 1, 8, 15, and 22. treatment repeats every 28 days for 4-6 courses in the absence of disease progression or unacceptable toxicity. quality of life is assessed at baseline and after 8 weeks of therapy. patients are followed every 3 months for 5 years.

Eligibility criteria:
disease characteristics: histologically confirmed stage iiib or iv non-small cell lung cancer measurable disease at least 1 lesion that is 2.0 cm or more in longest diameter cns metastases allowed if previously treated and clinically stable for at least 8 weeks prior to study no meningeal carcinomatosis participation in translational research component of this study is mandatory patient characteristics: age: 65 and over performance status: ecog 0-2 life expectancy: at least 12 weeks hematopoietic: platelet count at least 100,000/mm3 hemoglobin at least 10.0 g/dl absolute neutrophil count at least 1,500/mm3 hepatic: bilirubin no greater than 2.0 mg/dl renal: creatinine no greater than 2 times upper limit of normal other: no dysphagia or inability to swallow capsules intact no peripheral neuropathy grade 2 or greater no other significant medical condition that would preclude study no active infection within the past 2 weeks no other malignancy within the past 5 years prior concurrent therapy: biologic therapy: not specified chemotherapy: no prior chemotherapy for this disease within the past 5 years endocrine therapy: not specified radiotherapy: at least 3 weeks since prior radiotherapy and recovered no prior radiotherapy to more than 25% of bone marrow no prior radiotherapy to measurable lesion unless documented progression after therapy no concurrent radiotherapy, including palliative radiotherapy surgery: at least 3 weeks since prior major surgery

Keywords: stage iiib non-small cell lung cancer stage iv non-small cell lung cancer
4-weekly versus 12-weekly administration of bone-targeted agents in patients with bone metastases

Conditions: Breast Cancer; Prostate Cancer; Metastasis

Summary: the current rethinking clinical trials (react) trial will compare two schedules(12- vs. 4-weekly) of bone-targeting agents (btas) to evaluate quality of life, pain and skeletal events within the canadian health care system. this study will use an "integrated consent model" that involves "oral consent" rather than a written informed consent writing process as the study is comparing standard schedules and not a new administration schedule.

bone metastases are common in patients with advanced breast and prostate cancers. skeletal metastases can be associated with reduced quality of life (qol), pain and skeletal-related events (sres) (defined as pathological fractures, surgery/radiotherapy to bone, spinal cord compression and hypercalcaemia). maintaining qol while avoiding or delaying sres are the main goals of therapy. patients therefore receive bone-targeted agents (e.g. pamidronate, zoledronate and denosumab) which are typically given every 4 weeks. however, this 4 week dosing is based on convenience so the treatment could be given concurrently with chemotherapy. the half-life of these drugs in the bone is many months or even years. hence studies have been performed evaluating 12-weekly therapy. these have confirmed similar palliative outcomes in the 4 vs 12-weekly groups for both breast and prostate cancer patients. however, there remains clinical equipoise about which dosing interval physicians prescribe. the current trial will compare these two schedules of bone-targeting agents (12- vs. 4-weekly) to evaluate quality of life, pain and skeletal events within the canadian health care system. this study will use an "integrated consent model" that involves "oral consent" rather than a written informed consent writing process as the study is comparing standard schedules and not a new administration schedule.

Eligibility criteria:
inclusion criteria: * patients with either radiologically and/or histologically confirmed bone metastases from castrate resistant prostate cancer (36) or breast cancer. * about to start or currently receiving bta therapy. * serum creatinine \>30 ml/min and corrected serum calcium ≥ 2 mmol/l * age ≥ 18 years. * able to provide verbal consent exclusion criteria: * for crpc patients - definite contraindication for denosumab at baseline (e.g. hypocalcaemia \[albumin-corrected serum calcium \< 2.0 mmol/l\]). * history of or current evidence of osteonecrosis of the jaw. * radiotherapy or surgery to the bone planned within 4 weeks after randomization. * known hypersensitivity to trial drug or hypersensitivity to any other component of the trial drug (e.g. fructose). * any psychological, familial, sociological or geographical condition potentially hampering compliance with the trial protocol.
safety and efficacy study of in-111 pentetreotide to treat neuroendocrine tumors

Conditions: Neuroendocrine Tumors

Summary: the purpose of this study is to determine if high-dose 111in-pentetreotide known as neuroendomedix®, is an effective treatment for neuroendocrine tumors.


Eligibility criteria:
inclusion criteria: * patients must have received first line standard chemotherapy and/or radiation therapy for neuroendocrine malignancy in the past and failed the therapy. * patients must have evidence of residual multifocal active tumor. * all patients must sign an informed consent indicating the awareness of the investigational nature of the studies involved. * all patients must have a karnofsky performance status of at least 60. * patients must be greater than 18 years of age. * patients must have measurable and/or followable disease based on either clinical or radiologic exam. * sensitivity to indium-111 pentetreotide or any of its components is an absolute contraindication to participation in this trial. * an absolute contraindication is pregnancy as evidenced by the clinical condition, a positive pregnancy test (beta type human chorionic gonadotropin (β-hcg) or pelvic ultrasound). * if patients have received prior radionuclide therapy of the same product, there must be documented response to that therapy and/or residual active stable disease. exclusion criteria: * karnofsky performance status of 50 or less. * patients who are unable to give informed consent. * patients under 18 years of age. there will be no upper age discrimination. * patients who are pregnant or those potentially pregnant subjects not willing to practice effective contraceptive techniques during the study period. * patients with renal insufficiency as defined by a calculated creatinine clearance (based on age, weight and serum creatinine) of 39.9 ml/min or less.

Keywords: carcinoid islet cell cancer paraganglioma pheochromocytoma
a randomized controlled trial of a video decision aid in the icu

Conditions: Respiratory Failure; Cardiac Event

Summary: randomized controlled trial of a video decision aid in the icu in surrogates of admitted patients.


Eligibility criteria:
inclusion criteria: - age 65 or older patient does not have the capacity to make decisions patient admitted to the icu with life threatening illness including advanced heart, renal, lung, gastrointestinal and oncologic disease patient has english speaking representative to make decisions on his/her behalf patient critically ill and unlikely to survive to hospital discharge exclusion criteria: - patients who are imminently dying and admitted to the icu are excluded wards if the state

Keywords: icu
cardiovascular diseases in the silesian region in poland.

Conditions: Cardiovascular Diseases

Summary: the silesian cardiovascular database is an observational study of all patients hospitalized due to cardiovascular diseases. the date include information on the clinical characteristics, treatment modalities and prognosis in this population. the data include information on all the applicable diagnostic and therapeutic procedures, prognosis and hospitalization costs. likewise, data have been collected specialist care outpatient visits and primary health care patients were hospitalized.

the silesian cardiovascular database is an prospective observational study patients who were hospitalized in the silesian region in poland due to cardiovascular diseases from 1st january 2006. the aim of the study is to collect and analyze all epidemiological data, diagnostic and therapeutic procedures, in-hospital and long-term prognosis, hospitalization costs of these patients. likewise, data have been collected specialist care outpatient visits and primary health care patients were hospitalized. for the analysis were included patients hospitalized in the cardiology, cardiac surgery , diabetes, vascular surgery wards and who were hospitalized for cardiac diagnosis in the wards of internal medicine and intensive care. the silesian cardiovascular database was created based on the agreement between silesian centre for heart diseases in zabrze and the regional department of national health fund in katowice in order to conduct analyses and prepare scientific elaborations on the group of patients with circulatory system diseases. data elaboration and preparation for analyses was conducted by the science department of silesian centre for heart diseases and the department of biostatistics of medical university of silesia.

Eligibility criteria:
inclusion criteria: * each hospitalisation in the departments of: cardiology, cardiac surgery, diabetology and vascular surgery, * hospitalisation with cardiological diagnosis in the departments of internal medicine and intensive care. exclusion criteria: * hospitalisations of patients from beyond silesia province, * patients at the age below18 years at the moment of admission to the hospital

Keywords: cardiovascular diseases, prognosis
safety and efficacy of rad001 (everolimus) monotherapy plus best supportive care in patients with advanced gastric cancer (agc)

Conditions: Advanced Gastric Cancer

Summary: this study is designed to assess the safety and efficacy of rad001 monotherapy in patients with advanced gastric cancer which has progressed after one or two lines of prior chemotherapy.


Eligibility criteria:
inclusion criteria: * male or female patients \> 18 years old * histologically or cytologically confirmed and documented gastric adenocarcinoma * documented progression after 1 or 2 prior chemotherapy treatments for advanced disease * ecog performance status of \< 2 * lab parameters within specifically defined intervals * able to provide written informed consent exclusion criteria: * patients who have received \> 2 prior systemic therapies for advanced disease * administration of another anticancer therapy within 3 weeks prior to randomization * chronic treatment with steroids or another immunosuppressive agent * major surgery within 2 weeks prior to randomization * patients with cns metastases * any other severe and/or uncontrolled medical condition other protocol-defined inclusion/exclusion criteria may apply

Keywords: gastric cancer, advanced gastric cancer, stomach neoplasm, stomach disease, adenocarcinoma of stomach, gi neoplasm
sd, il-13 production rate in ipf

Conditions: Idiopathic Pulmonary Fibrosis

Summary: the purpose of this study is to investigate how qax576 affects levels of interleukin 13 (il-13) in patients with idiopathic pulmonary fibrosis (ipf).


Eligibility criteria:
inclusion criteria: * men and women between the ages of 40 and 80 years with a confirmed diagnosis of idiopathic pulmonary fibrosis * both men and women must be on non-childbearing potential. additional information regarding this requirement is available at screening. * capability to meet certain lung function tests at screening * non-smokers * no participation in another clinical study within 4 weeks of study start. exclusion criteria: * certain medical conditions may exclude candidates from participation. * blood loss or donation of 400 ml or more within 2 months of study start significant illness (other than respiratory) within 2 weeks of study start * past medical personal or close family history of clinically significant ecg abnormalities * connective tissue disorders * active infection or history of systemic parasitic infection * known hypersensitivity to the drug. * history of immunocompromise, including a positive hiv test result. * history of drug or alcohol abuse within 12 months of study start * any condition that may compromise patient safety

Keywords: idiopathic pulmonary fibrosis
preliminary study of the scale to assess ataxia and neurologic dysfunction (stand)

Conditions: Spinocerebellar Ataxia - All Sub-types; Friedreich's Ataxia

Summary: the objectives of this study are: * to validate the inter-rater and intra-rater reliability of a new scale for the assessment of ataxia and neurologic dysfunction (stand) * to assess common constructs and correlation between stand subscale items.

there are few validated, comprehensive rating scales for the assessment of ataxia severity. the development of a scale to assess ataxia and neurologic dysfunction (stand) would examine and measure as many facets of ataxia as possible. scale items to be measured include parkinsonism, timed gait analysis, dystonia, neuropathy and peripheral nerve weakness, as well as other areas of clinical manifestation for ataxia. this brief but thorough scale should yield a thorough measurement of ataxia.

Eligibility criteria:
inclusion criteria: * diagnosis of ataxia. * male or female between 18 and 80 years of age. * subject has voluntarily signed an irb approved informed consent form to participate in the study after all relevant aspects of the study have been explained and discussed with the subject. exclusion criteria: * any illness that in the investigator's opinion preclude participation in this study. * subjects with a cardiac pacemaker * legal incapacity or limited legal capacity.